Gauthier Marie-Soleil, Miyoshi Hideaki, Souza Sandra C, Cacicedo José M, Saha Asish K, Greenberg Andrew S, Ruderman Neil B
Diabetes and Metabolism Unit, Department of Medicine Section of Endocrinology, Boston University Medical Center, Boston, Massachusetts 02118, USA.
J Biol Chem. 2008 Jun 13;283(24):16514-24. doi: 10.1074/jbc.M708177200. Epub 2008 Apr 5.
AMP-activated protein kinase (AMPK) is activated in adipocytes during exercise and other states in which lipolysis is stimulated. However, the mechanism(s) responsible for this effect and its physiological relevance are unclear. To examine these questions, 3T3-L1 adipocytes were treated with cAMP-inducing agents (isoproterenol, forskolin, and isobutylmethylxanthine), which stimulate lipolysis and activate AMPK. When lipolysis was partially inhibited with the general lipase inhibitor orlistat, AMPK activation by these agents was also partially reduced, but the increases in cAMP levels and cAMP-dependent protein kinase (PKA) activity were unaffected. Likewise, small hairpin RNA-mediated silencing of adipose tissue triglyceride lipase inhibited both forskolin-stimulated lipolysis and AMPK activation but not that of PKA. Forskolin treatment increased the AMP:ATP ratio, and this too was reduced by orlistat. When acyl-CoA synthetase, which catalyzes the conversion of fatty acids to fatty acyl-CoA, was inhibited with triacsin C, the increases in both AMPK activity and AMP:ATP ratio were blunted. Isoproterenol-stimulated lipolysis was accompanied by an increase in oxidative stress, an effect that was quintupled in cells incubated with the AMPK inhibitor compound C. The isoproterenol-induced increase in the AMP:ATP ratio was also much greater in these cells. In conclusion, the results indicate that activation of AMPK in adipocytes by cAMP-inducing agents is a consequence of lipolysis and not of PKA activation. They suggest that AMPK activation in this setting is caused by an increase in the AMP:ATP ratio that appears to be due, at least in part, to the acylation of fatty acids. Finally, this AMPK activation appears to restrain the energy depletion and oxidative stress caused by lipolysis.
在运动及其他刺激脂肪分解的状态下,脂肪细胞中的AMP激活蛋白激酶(AMPK)会被激活。然而,导致这种效应的机制及其生理相关性尚不清楚。为了研究这些问题,用cAMP诱导剂(异丙肾上腺素、福斯高林和异丁基甲基黄嘌呤)处理3T3-L1脂肪细胞,这些诱导剂可刺激脂肪分解并激活AMPK。当用通用脂肪酶抑制剂奥利司他部分抑制脂肪分解时,这些试剂对AMPK的激活也会部分降低,但cAMP水平和cAMP依赖性蛋白激酶(PKA)活性的增加不受影响。同样,小发夹RNA介导的脂肪组织甘油三酯脂肪酶沉默抑制了福斯高林刺激的脂肪分解和AMPK激活,但不影响PKA的激活。福斯高林处理增加了AMP:ATP比值,而这也被奥利司他降低。当用三辛脂素C抑制催化脂肪酸转化为脂肪酰辅酶A的酰基辅酶A合成酶时,AMPK活性和AMP:ATP比值的增加均受到抑制。异丙肾上腺素刺激的脂肪分解伴随着氧化应激的增加,在用AMPK抑制剂化合物C孵育的细胞中,这种效应增加了五倍。在这些细胞中,异丙肾上腺素诱导的AMP:ATP比值增加也大得多。总之,结果表明,cAMP诱导剂激活脂肪细胞中的AMPK是脂肪分解的结果,而非PKA激活所致。它们表明,在这种情况下,AMPK激活是由AMP:ATP比值增加引起的,这似乎至少部分归因于脂肪酸的酰化。最后,这种AMPK激活似乎抑制了脂肪分解引起的能量消耗和氧化应激。